Glycosylation-Engineered Platelet Membrane-Coated Interleukin 10 Nanoparticles for Targeted Inhibition of Vascular Restenosis
Fengshi Li,Zhihua Rong,Tianqi Chen,Peng Wang,Xiao Di,Leng Ni,Changwei Liu
DOI: https://doi.org/10.2147/IJN.S423186
IF: 7.033
2023-09-06
International Journal of Nanomedicine
Abstract:Fengshi Li, 1, &ast Zhihua Rong, 1, &ast Tianqi Chen, 2 Peng Wang, 1 Xiao Di, 1 Leng Ni, 1 Changwei Liu 1 1 Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China; 2 Department of Medical Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China &astThese authors contributed equally to this work Correspondence: Leng Ni; Changwei Liu, Tel +86 010 69152500 ; +86 010 69152501, Email ; Purpose: The purpose of this study was to improve the immune compatibility and targeting abilities of IL10 nanoparticles coated with platelet membrane (IL10-PNPs) by glycosylation engineering in order to effectively reduce restenosis after vascular injury. Materials and Methods: In this study, we removed sialic acids and added α (1,2)-fucose and α (1,3)-fucose to platelet membrane glycoprotein, thus engineering the glycosylation of IL10-PNPs (IL10-GE-PNPs). In vitro and in vivo experiments were conducted to evaluate the targeting and regulatory effects of IL10-GE-PNPs on macrophage polarization, as well as the influence of IL10-GE-PNPs on the phenotypic transformation, proliferation, and migration of smooth muscle cells, and its potential in promoting the repair function of endothelial cells within an inflammatory environment. In order to assess the distribution of IL10-GE-PNP in different organs, in vivo imaging experiments were conducted. Results: IL10-GE-PNPs were successfully constructed and demonstrated to effectively target and regulate macrophage polarization in both in vitro and in vivo settings. This regulation resulted in reduced proliferation and migration of smooth muscle cells and promoted the repair of endothelial cells in an inflammatory environment. Consequently, restenosis after vascular injury was reduced. Furthermore, the deposition of IL10-GE-PNPs in the liver and spleen was significantly reduced compared to IL10-PNPs. Conclusion: IL10-GE-PNPs emerged as a promising candidate for targeting vascular injury and exhibited potential as an innovative drug delivery system for suppressing vascular restenosis. The engineered glycosylation of IL10-PNPs improved their immune compatibility and targeting abilities, making them an excellent therapeutic option. Keywords: vascular restenosis, platelet membrane, glycosylation, interleukin 10, targeting delivery Atherosclerosis-related cardiovascular diseases remain the leading cause of death and disability worldwide. 1 Interventional angioplasty is a common treatment for these diseases to reconstruct vascular patency. Angioplasty has been shown to lead to vascular injury, resulting in vascular restenosis, which has a high reintervention rate and has a negative effect on the patient's prognosis. 2,3 Local de-endothelialization damage causes immune cells and platelets to be recruited into the injured vessel wall. Smooth muscle cells (SMCs) proliferate and migrate as a consequence of inflammatory cytokines secreted by immune cells and platelets, leading to vascular restenosis. 4 At the site of restenosis, macrophages play a critical role in inflammatory reactions. During the formation of vascular restenosis, macrophages are active, polarize into the M1 phenotype and secrete cytokines such as IL-1β, TNF-α, and IL-6, which transform SMCs into the secretory cell type, contributing to the proliferation and migration of the cells. 5 Alternatively activated macrophages, called the M2 phenotype, result in a significant decrease in vascular restenosis, inhibiting smooth muscle cell phenotypic transformation and promoting endothelial cell repair by different cytokine secretion profiles. Consequently, targeted stimulation of macrophage polarization into the M2 phenotype is an effective method for preventing vascular restenosis. 6 Interleukin 10 (IL10) is an all-encompassing anti-inflammatory cytokine with immunoregulatory roles. 7 IL10 is recognized for its various mechanisms in governing M2 macrophage polarization. 8 Nevertheless, the systemic administration of IL10 leads to adverse reactions, including anemia and thrombocytopenia. 9 In preceding investigations, nanoparticles containing IL10 were formulated with the aim of suppressing the localized inflammatory response within atherosclerotic lesions. 10,11 The hemostasis function of platelets has long been known. In recent years, platelets were shown to play a critical role in inflammatory reacti -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology